A Phase 4 interventional study of Clozapine in Schizophrenia and Psychosis, sponsored by Jimmi Nielsen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Jimmi Nielsen · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing clozapine in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. Clozapine · Schizophrenia.
Among the 37 studies testing clozapine in Schizophrenia, this one is the 7th largest by planned enrollment, is one of 2 that started in 2021, is one of 21 in phase 4, and was the 31st registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 37 studies testing clozapine in Schizophrenia are open now, in 8 countries. Recruiting first, the newest first:
Northwell Health · Sites in United States, Canada
Ages 18–35
Dr. Inge Winter · Sites in Austria, Germany, Italy and 2 more countries
Ages 18–70
New York State Psychiatric Institute · Sites in United States
Ages 18–65
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–60
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Clozapine: first FDA approval 1989 (CLOZARIL). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 41 across the 37 interventional studies. Of the 24 that completed or were terminated, 6 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 37 have an industry lead sponsor. The 10 most frequent:
Jimmi Nielsen is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Jimmi Nielsen has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies testing clozapine in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04580134University of Texas Southwestern Medical CenterCLOZAPINE Response in Biotype-1 | 2027-04-30 |
| NCT02639702Centre for Addiction and Mental HealthSwitching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies testing clozapine in Schizophrenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The outline of the current project is to establish a cohort of patients with treatment refractory schizophrenia eligible for clozapine, to identify clinical and biological characteristics of clozapine responding patients. Patients will be offered treatment with clozapine according to national clinical guidelines. Before clozapine is initiated, patients will be offered a thoroughly neurobiological examination, and re-examination will be carried out after 12 weeks of treatment. The primary focus of the examinations will be immunological markers and autoantibodies in the blood and cerebrospinal fluid, permeability of the blood-brain barrier and magnetic resonance imaging of structural, neurochemical and functional brain changes.
Patients will be examined before and after 12 weeks of treatment with clozapine
Examinations at baseline and follow up will be:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
According to information from patient and available files, noUncontrolled
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label clozapine will be given to all participants in clinical doses adjusted to sideeffects and clinical effect
Drug: Clozapine
clinical doses adjusted to sideeffects and clinical effect
Qalb
Quotient albumin (Qabl) in cerebrospinal fluid (CSF) compared to plasma
Time frame: Baseline
Change in Qalb
Change in quotient albumin in cerebrospinal fluid compared to plasma
Time frame: Baseline and after 12 weeks
Change in IL-6 and TGF-beta
Change in interleukin 6 (IL-6) and transcription growth factor beta (TGF-beta)
Time frame: Baseline and after 12 weeks
Change in FA, MD, AD and RD
Change in fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD)
Time frame: Baseline and after 12 weeks
Change in cortical thickness as measured with FreeSurfer
Change in cortical thickness as measured with FreeSurfer
Time frame: Baseline and after 12 weeks
Change in glutamate in ACC and thalamus measured with MTI
Change in glutamate in anterior cingulate cortex (ACC) and thalamus measured with magnetic transfer imaging (MTI)
Time frame: Baseline and after 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2021 (actual). Primary completion is estimated for Dec 2029, 106 months after the start.
Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 106 months is above that.
Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clozapine
Jimmi Nielsen